Cargando…
Alisporivir Inhibition of Hepatocyte Cyclophilins Reduces HBV Replication and Hepatitis B Surface Antigen Production
BACKGROUND & AIMS: Cyclophilins are host factors required for hepatitis C virus replication. Cyclophilin inhibitors such as alisporivir have shown strong anti–hepatitis C virus activity in vitro and in clinical studies. However, little is known about whether hepatocyte cyclophilins are involved...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AGA Institute. Published by Elsevier Inc.
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7172380/ https://www.ncbi.nlm.nih.gov/pubmed/25305505 http://dx.doi.org/10.1053/j.gastro.2014.10.004 |
_version_ | 1783524246593470464 |
---|---|
author | Phillips, Sandra Chokshi, Shilpa Chatterji, Udayan Riva, Antonio Bobardt, Michael Williams, Roger Gallay, Philippe Naoumov, Nikolai V. |
author_facet | Phillips, Sandra Chokshi, Shilpa Chatterji, Udayan Riva, Antonio Bobardt, Michael Williams, Roger Gallay, Philippe Naoumov, Nikolai V. |
author_sort | Phillips, Sandra |
collection | PubMed |
description | BACKGROUND & AIMS: Cyclophilins are host factors required for hepatitis C virus replication. Cyclophilin inhibitors such as alisporivir have shown strong anti–hepatitis C virus activity in vitro and in clinical studies. However, little is known about whether hepatocyte cyclophilins are involved in the hepatitis B virus (HBV) life cycle. We investigated the effects of 2 cyclophilin inhibitors (alisporivir and NIM811) on HBV replication and hepatitis B surface antigen (HBsAg) production in cell lines. METHODS: Liver-derived cell lines producing full-length HBV and HBsAg particles, owing to stable (HepG2215) or transient (HuH-7) transfection, or infected with HBV (HepaRG cells; Invitrogen [Carlsbad, CA]), were incubated with alisporivir or NIM811 alone, or alisporivir in combination with a direct antiviral (telbivudine). The roles of individual cyclophilins in drug response was evaluated by small interfering RNA knockdown of cyclophilin (CYP)A, CYPC, or CYPD in HepG2215 cells, or CYPA knockdown in HuH-7 cells. The kinetics of antiviral activity were assessed based on levels of HBV DNA and HBsAg and Southern blot analysis. RESULTS: In HepG2215, HuH-7, and HepaRG cells, alisporivir reduced intracellular and secreted HBV DNA, in a dose-dependent manner. Knockdown of CYPA, CYPC, or CYPD (reduced by 80%) significantly reduced levels of HBV DNA and secreted HBsAg. Knockdown of CYPA significantly reduced secretion of HBsAg, leading to accumulation of intracellular HBsAg; the addition of alisporivir greatly reduced levels of HBsAg in these cells. The combination of alisporivir and telbivudine had greater antiviral effects than those of telbivudine or alisporivir alone. CONCLUSIONS: Alisporivir inhibition of cyclophilins in hepatocyte cell lines reduces replication of HBV DNA and HBsAg production and secretion. These effects are potentiated in combination with direct antiviral agents that target HBV-DNA polymerase. |
format | Online Article Text |
id | pubmed-7172380 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | AGA Institute. Published by Elsevier Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-71723802020-04-22 Alisporivir Inhibition of Hepatocyte Cyclophilins Reduces HBV Replication and Hepatitis B Surface Antigen Production Phillips, Sandra Chokshi, Shilpa Chatterji, Udayan Riva, Antonio Bobardt, Michael Williams, Roger Gallay, Philippe Naoumov, Nikolai V. Gastroenterology Original Research BACKGROUND & AIMS: Cyclophilins are host factors required for hepatitis C virus replication. Cyclophilin inhibitors such as alisporivir have shown strong anti–hepatitis C virus activity in vitro and in clinical studies. However, little is known about whether hepatocyte cyclophilins are involved in the hepatitis B virus (HBV) life cycle. We investigated the effects of 2 cyclophilin inhibitors (alisporivir and NIM811) on HBV replication and hepatitis B surface antigen (HBsAg) production in cell lines. METHODS: Liver-derived cell lines producing full-length HBV and HBsAg particles, owing to stable (HepG2215) or transient (HuH-7) transfection, or infected with HBV (HepaRG cells; Invitrogen [Carlsbad, CA]), were incubated with alisporivir or NIM811 alone, or alisporivir in combination with a direct antiviral (telbivudine). The roles of individual cyclophilins in drug response was evaluated by small interfering RNA knockdown of cyclophilin (CYP)A, CYPC, or CYPD in HepG2215 cells, or CYPA knockdown in HuH-7 cells. The kinetics of antiviral activity were assessed based on levels of HBV DNA and HBsAg and Southern blot analysis. RESULTS: In HepG2215, HuH-7, and HepaRG cells, alisporivir reduced intracellular and secreted HBV DNA, in a dose-dependent manner. Knockdown of CYPA, CYPC, or CYPD (reduced by 80%) significantly reduced levels of HBV DNA and secreted HBsAg. Knockdown of CYPA significantly reduced secretion of HBsAg, leading to accumulation of intracellular HBsAg; the addition of alisporivir greatly reduced levels of HBsAg in these cells. The combination of alisporivir and telbivudine had greater antiviral effects than those of telbivudine or alisporivir alone. CONCLUSIONS: Alisporivir inhibition of cyclophilins in hepatocyte cell lines reduces replication of HBV DNA and HBsAg production and secretion. These effects are potentiated in combination with direct antiviral agents that target HBV-DNA polymerase. AGA Institute. Published by Elsevier Inc. 2015-02 2014-10-08 /pmc/articles/PMC7172380/ /pubmed/25305505 http://dx.doi.org/10.1053/j.gastro.2014.10.004 Text en Copyright © 2015 AGA Institute. Published by Elsevier Inc. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Original Research Phillips, Sandra Chokshi, Shilpa Chatterji, Udayan Riva, Antonio Bobardt, Michael Williams, Roger Gallay, Philippe Naoumov, Nikolai V. Alisporivir Inhibition of Hepatocyte Cyclophilins Reduces HBV Replication and Hepatitis B Surface Antigen Production |
title | Alisporivir Inhibition of Hepatocyte Cyclophilins Reduces HBV Replication and Hepatitis B Surface Antigen Production |
title_full | Alisporivir Inhibition of Hepatocyte Cyclophilins Reduces HBV Replication and Hepatitis B Surface Antigen Production |
title_fullStr | Alisporivir Inhibition of Hepatocyte Cyclophilins Reduces HBV Replication and Hepatitis B Surface Antigen Production |
title_full_unstemmed | Alisporivir Inhibition of Hepatocyte Cyclophilins Reduces HBV Replication and Hepatitis B Surface Antigen Production |
title_short | Alisporivir Inhibition of Hepatocyte Cyclophilins Reduces HBV Replication and Hepatitis B Surface Antigen Production |
title_sort | alisporivir inhibition of hepatocyte cyclophilins reduces hbv replication and hepatitis b surface antigen production |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7172380/ https://www.ncbi.nlm.nih.gov/pubmed/25305505 http://dx.doi.org/10.1053/j.gastro.2014.10.004 |
work_keys_str_mv | AT phillipssandra alisporivirinhibitionofhepatocytecyclophilinsreduceshbvreplicationandhepatitisbsurfaceantigenproduction AT chokshishilpa alisporivirinhibitionofhepatocytecyclophilinsreduceshbvreplicationandhepatitisbsurfaceantigenproduction AT chatterjiudayan alisporivirinhibitionofhepatocytecyclophilinsreduceshbvreplicationandhepatitisbsurfaceantigenproduction AT rivaantonio alisporivirinhibitionofhepatocytecyclophilinsreduceshbvreplicationandhepatitisbsurfaceantigenproduction AT bobardtmichael alisporivirinhibitionofhepatocytecyclophilinsreduceshbvreplicationandhepatitisbsurfaceantigenproduction AT williamsroger alisporivirinhibitionofhepatocytecyclophilinsreduceshbvreplicationandhepatitisbsurfaceantigenproduction AT gallayphilippe alisporivirinhibitionofhepatocytecyclophilinsreduceshbvreplicationandhepatitisbsurfaceantigenproduction AT naoumovnikolaiv alisporivirinhibitionofhepatocytecyclophilinsreduceshbvreplicationandhepatitisbsurfaceantigenproduction |